The Use of Intravenous Therapy. Nursing Standard

Total Page:16

File Type:pdf, Size:1020Kb

The Use of Intravenous Therapy. Nursing Standard IV therapy focus CONTINUING PROFESSIONAL DEVELOPMENT Fluid management By reading this article and writing a practice profile, you can gain The use of intravenous therapy 47-52 ten continuing education points (CEPs). You have up to a year to Multiple-choice questions send in your practice profile. Guidelines on how to write and and submission instructions 54 Practice profile submit a profile are featured immediately after the continuing assessment guide 55 professional development article every week. Practice profile 27 The use of intravenous therapy NS98 Hand H (2001) The use of intravenous therapy. Nursing Standard. 15, 43, 47-52. In brief Date of acceptance: October 10 2000. Author Helen Hand BSc(Hons), between different body compartments, as well as Aims and intended learning outcomes MA(Ed), RGN, is Lecturer, knowledge of the actions of the various solutions School of Nursing and The aim of this article is to increase your under- available. Midwifery, University of standing of fluid and electrolyte homeostasis, and Sheffield. Email: provide the rationale for the care and manage- [email protected] Body fluid compartments ment of patients undergoing intravenous fluid therapy. After reading this article, you should be The total amount of water in a male weighing Summary able to: 70kg is around 40L. Almost two thirds by volume Nurses have a professional I Describe different body fluid compartments. (25L) is contained in the intracellular fluid (ICF) and legal responsibility to I Define the principles of osmosis, diffusion and compartment, which consists of trillions of cells. understand the rationale for the use of prescribed fluids. filtration in relation to the movement of water The remaining one-third (15L) is found in the Safe administration requires and solutes between compartments. extracellular fluid (ECF) compartment (outside an understanding of the role I Differentiate between hypotonic, isotonic and the cells). The ECF compartment is divided into of electrolytes and water and hypertonic solutions. two sub-compartments: the plasma (3L), the of the mechanisms of I Understand the role of electrolytes in fluid fluid portion of blood in the blood vessels, and movement between different balance. the interstitial fluid (12L) which bathes the body body compartments. I Identify the signs and symptoms of fluid and cells. electrolyte imbalance. There are numerous other examples of ECF Key words I Explain the different reasons for commencing that are distinct from blood plasma and inter- I Intravenous therapy I intravenous fluid therapy. stitial fluid (ISF), such as cerebrospinal fluid, Nursing: care I State the different types of intravenous fluid synovial fluid, lymph, serous fluid and secretions These key words are based and give a rationale for their use. from the gastrointestinal (GI) tract. on subject headings from the I Analyse the nurse’s role in observing and sup- The fluid compartments are separated from British Nursing Index. This porting the patient undergoing intravenous one another by semi-permeable membranes. article has been subject to fluid therapy. Water and small molecules pass through the double-blind review. membrane, whereas larger colloid substances Introduction and proteins are confined to the intravascular space. The composition of each compartment is Knowledge of different parenteral fluids and maintained by the selectivity of its membrane. their method of action is essential to the safe The intravascular fluid (IVF) is separated from the delivery of infusion therapy. Nurses have a profes- ISF by the capillary membrane, and between the Online archive sional and legal responsibility to understand ISF and the ICF is the cell membrane. The con- For related articles visit our the rationale for the use of specific prescribed trolled movement of fluids and solutes between online archive at: fluids and the desired and untoward effects of these spaces ensures that vital nutrients can pass www.nursing-standard.co.uk administration. Safe administration demands an from the IVF to the cells, and that waste prod- and search using the key understanding of the role of electrolytes and ucts can move out of the cells and into the IVF. words above. water and of the mechanisms of movement The body fluid compartments are maintained at CONTINUING PROFESSIONAL DEVELOPMENT Fluid management Fig 1. Osmosis energy. In the body, the diffusion of substances takes place across a selectively permeable plasma membrane and will only occur if the molecules Semi-permeable membrane are small enough to pass through. Facilitated diffusion This makes use of highly selective ‘carrier molecules’ situated in the cell membrane. This is used by large lipid insoluble molecules, such as glucose, to gain rapid entry into cells. If the carriers became saturated, diffusion will be reduced even though a diffusion gradient still exists. Higher concentration Lower concentration TIME OUT 1 Using an anatomy and physiology text, list at least five substances that move across the cell membrane by diffusion. Filtration This is a passive process; there is a Non-permeable solutes gradient on either side of the membrane, but this time it is pressure rather than solute concentration. a constant level by the homeostatic mechanisms Hydrostatic pressure forces water and small Box 1. Homeostatic listed in Box 1. dissolved molecules out of the plasma into the mechanisms Osmosis This is the movement of water through ISF. This movement occurs at blood capillary a selectively permeable membrane, that is, one level, fluids and small molecules leaving the I Osmosis that allows only certain substances to cross (Fig. 1). blood to supply nutrients and raw materials to I Diffusion Pores in the membrane allow the movement of the cells for use in metabolic processes. Filtration I Facilitated diffusion water molecules, from an area of low solute is also important in urine formation. The hydro- I Filtration concentration to an area of high solute static pressure at the nephron causes water and I Active transport concentration. For example, if a glucose solution other molecules to pass through the tubule in is separated from pure water by a membrane the first stage of urine production. that is permeable to water, but not permeable to If fluid is forced out of the capillary by hydro- large glucose molecules, water will diffuse from static pressure, it will be drawn back into the the area of high water concentration (pure blood supply at some point to maintain overall water) to the area of low concentration (the blood volume. This is achieved by the presence glucose solution), to equalise the concentration of plasma proteins in the blood which attract of the two solutions. water by osmosis. Plasma proteins, such as Diffusion Diffusion is the movement of albumin, are unable to leave the capillary, which substances from an area of high concentration means that the blood is more concentrated in to an area of low concentration. This is called a terms of plasma proteins and has a low water diffusion gradient. Because of the random concentration compared to ISF, which has a high movement of molecules and the collisions that water (and low plasma protein) concentration. result from this movement, molecules of a given Water, therefore, moves by osmosis from the type will eventually be evenly distributed area of high water concentration (ISF) to the throughout a system. This process can be seen, area of low water concentration (blood) to for example, when ink is dropped into a glass of equalise the two compartments. water or when perfume is sprayed into a room. Water is driven out of the arteriolar end of the The ink spreads evenly throughout the water capillary because hydrostatic pressure is greater and the perfume spreads evenly throughout the than the plasma oncotic pressure, generated by air in the room. The net movement of ink the plasma proteins. As water is forced out, molecules and perfume molecules is from a however, the hydrostatic pressure decreases and region of high concentration to one of low is eventually exceeded by the plasma oncotic concentration – in other words they move down pressure. This pressure difference favours the a concentration gradient. drawing back of water to the capillary from the Diffusion is a passive process, it does not require interstitial space. In this way, essential nutrition CONTINUING PROFESSIONAL DEVELOPMENT Fluid management is supplied and waste products are removed water represents the most extreme example of Box 2. Causes of from cells and brought into the bloodstream for hypotonicity as it contains no solutes at all. If a hyponatraemia excretion, and the overall blood volume is main- cell were placed into a solution of distilled tained. Any fluid that is not returned directly to water, it would continue to gain water until it I Prolonged diuretic use the bloodstream is returned by the lymphatic eventually burst. I Excessive diaphoresis system, which drains the interstitial space. (sweating) I Prolonged vomiting/ Plasma protein concentration is, therefore, an TIME OUT 2 diarrhoea important factor in the maintenance and distri- Make a list of the intravenous I Extensive burns bution of fluid extracellular compartments. infusion solutions commonly I Renal disease Active transport Where no electrical or used in your clinical area. I Over infusion of dextrose concentration gradient exists, substances are Decide whether they are 5% unable to move by simple diffusion and, isotonic, hypertonic or hypotonic I Anorexia, fasting, therefore, have to be ‘actively transported’. This and state what effect they would have on alcoholism requires the use of energy in the form of cells placed in them. I Syndrome of inappropriate adenosine triphosphate (ATP), to move substances antidiuretic hormone (ADH) against a pressure or concentration gradient. The I Adrenal impairment I sodium-potassium pump on the cell membrane Cirrhosis Electrolytes I that is responsible for maintaining intracellular Congestive cardiac failure I Drugs, such as intravenous fluid volume best illustrates this concept.
Recommended publications
  • Intravenous Therapy Procedure Manual
    INTRAVENOUS THERAPY PROCEDURE MANUAL - 1 - LETTER OF ACCEPTANCE __________________________________________ hereby approves (Facility) the attached Reference Manual as of _____________________. (Date) The Intravenous Therapy Procedure Manual will be reviewed at least annually or more often when deemed appropriate. Revisions will be reviewed as they occur. Current copies of the Intravenous Therapy Procedure Manual shall be maintained at each appropriate nursing station. I have reviewed this manual and agree to its approval. __________________________ (Administrator) __________________________ (Director of Nursing) __________________________ (Medical Director) - 2 - TABLE OF CONTENTS TABLE OF CONTENTS INTRODUCTION A. Purpose 1 B. Local Standard of Practice 1 RESPONSIBILITIES A. Responsibilities: M Chest Pharmacy 1 B. Responsibilities: Administrator 1 C. Responsibilities: Director of Nursing Services (DON/DNS) 1 D. Skills Validation 2 AMENDMENTS GUIDELINES A. Resident Candidacy for IV Therapy 1 B. Excluded IV Medications and Therapies 1 C. Processing the IV Order 1 D. IV Solutions/Medications: Storage 2 E. IV Solutions/Medications: Handling 3 F. IV Solutions and Supplies: Destroying and Returning 4 G. IV Tubing 5 H. Peripheral IV Catheters and Needles 6 I. Central Venous Devices 7 J. Documentation and Monitoring 8 K. IV Medication Administration Times 9 L. Emergency IV Supplies 10 I TABLE OF CONTENTS PROTOCOLS A. IV Antibiotic 1 1. Purpose 2. Guidelines 3. Nursing Responsibilities B. IV Push 2 1. Purpose 2. Guidelines C. Anaphylaxis Allergic Reaction 4 1. Purpose 2. Guidelines 3. Nursing Responsibilities and Interventions 4. Signs and Symptoms of Anaphylaxis 5. Drugs Used to Treat Anaphylaxis 6. Physician Protocol PRACTICE GUIDELINES A. Purpose 1 B. Personnel 1 C. Competencies 1 D.
    [Show full text]
  • Attachment 3
    CURRICULUM CLINICAL BASE / CA-1 / CA-2 / CA-3 ANESTHESIOLOGY RESIDENCY PROGRAM GOALS AND OBJECTIVES AND CORE COMPETENCIES Department of Anesthesiology University of Missouri at Kansas City School of Medicine Saint Luke’s Hospital Truman Medical Center Children’s Mercy Hospital Revised 2011 Table of Contents Pages Introduction – Statement of Curriculum ................................................................................................................... 3 I. Rendering Patient Insensible to Pain ............................................................................................................. 4-10 II. Support of Life Functions ............................................................................................................................. 11-16 III. Clinical Base Year A. Cardiology ................................................................................................................................................. 17-32 B. Emergency Medicine ................................................................................................................................. 33-44 C. General Medicine ....................................................................................................................................... 45-49 D. Infectious Disease ...................................................................................................................................... 50-59 E. Nephrology ..............................................................................................................................................
    [Show full text]
  • Nicotine Patches Appear Safe for CAD Patients
    May 1, 2007 • www.internalmedicinenews.com Cardiovascular Medicine 37 Nicotine Patches Appear Safe for CAD Patients BY BRUCE JANCIN 30%, but many physicians have been re- induced myocardial defect on single-photon ment arm jumped from 10.9 to 25.2 Denver Bureau luctant to recommend it for their patients emission computed tomography (SPECT) ng/mL, Dr. Leja said. After 1 week, patients with coronary artery disease (CAD) be- to receive either 21-mg nicotine patches or were encouraged to quit smoking while N EW O RLEANS — Nicotine patches cause nicotine is known to increase heart placebo in addition to continuing their usu- continuing to use their assigned patches. are safe for use in smokers with known rate and blood pressure, and can induce al amount of cigarette smoking. The pri- Upon SPECT imaging at week 4, the coronary artery disease and stress-induced vasoconstriction as well, Dr. Monika J. Leja mary end point of the study was change in size of the perfusion defects in the nico- myocardial ischemia, according to the re- reported at the annual scientific session of total perfusion defect size upon repeat stress tine patch group remained unchanged sults of the first-ever randomized, place- the American College of Cardiology. SPECT imaging performed at 1 week. from baseline, although their plasma nico- bo-controlled, multicenter clinical trial to Dr. Leja and her coinvestigators at the There was no change in the total or is- tine levels remained as high as at week 1. examine this issue. Methodist DeBakey Heart Center in Hous- chemic perfusion defect size, compared The trial was supported by Glaxo- Nicotine replacement therapy doubles ton randomized 55 heavy smokers with with baseline, in either group even though SmithKline Consumer Healthcare.
    [Show full text]
  • Intravenous Infusion Drug Administration: Flushing Guidance
    Intravenous Infusion Drug Administration: Flushing Guidance April 2019 Acknowledgements: Andrew Barton – Author/reviewer NIVAS Chair Advanced Nurse Practitioner, IV Therapy and Vascular Access Frimley Health NHS Foundation Trust Tim Jackson – Reviewer/contributor, NIVAS Board Deputy Chair Consultant in Anesthesia & Intensive Care Medicine Calderdale & Huddersfield NHS Foundation Trust Gemma Oliver - Reviewer/contributor NIVAS Board Nurse Consultant, Integrated IV Care East Kent Hospitals NHS Foundation Trust Nicola York - Reviewer/contributor NIVAS Board Clinical Nurse Manager Vascular Access and Nutrition support Oxford University Hospitals NHS Foundation Trust Matt Jones - Reviewer/contributor NIVAS Board Consultant Anaesthetist East Kent Hospitals NHS Foundation Trust Steve Hill - Reviewer/contributor NIVAS Board Procedural Team Manger The Christie NHS Foundation Trust Marie Woodley - Reviewer/contributor NIVAS Board Clinical Nurse Specialist IV therapy/OPAT Lead Buckinghamshire Healthcare Trust Contents: Introduction………………………………………………………………………… Page 1 Methods of administering intravenous therapy………………………………… Page 2 Intravenous bolus injection…………………………………………….… Page 2 Continuous, variable dose syringe driver injection……………………. Page 2 Intravenous infusion…………………………………………………….… Page 3 Option 1: Discarding the infusion set………………………………….… Page 3 Option 2: Flushing the Infusion set manually…………………………... Page 4 Option 3: Flushing the infusion set with a closed system…………….. Page 4 General Guidance…………………………………………………………………. Page 5 Conclusion………………………………………………………………………….
    [Show full text]
  • Intravenous Therapytherapy
    IntravenousIntravenous TherapyTherapy Department of EMS Professions Temple College IVIV TherapyTherapy OverviewOverview I DefinitionsDefinitions && IndicationsIndications I FluidFluid ResuscitationResuscitation I EquipmentEquipment andand SuppliesSupplies I ChoosingChoosing FluidsFluids andand CathetersCatheters I ProcedureProcedure andand TechniqueTechnique TipsTips – Peripheral Venipuncture – Intraosseous Access I PotentialPotential ComplicationsComplications DefinitionsDefinitions I IVIV // VenipunctureVenipuncture I CrystalloidsCrystalloids I PeripheralPeripheral // CentralCentral I ColloidsColloids I IntraosseousIntraosseous AccessAccess I HypertonicHypertonic I FluidFluid ResuscitationResuscitation I IsotonicIsotonic I MedicationMedication AccessAccess I DripDrip RatesRates I KVOKVO // TKOTKO IndicationsIndications forfor VenipunctureVenipuncture I VolumeVolume I VenousVenous AccessAccess toto – Dehydration CirculationCirculation I Water – Blood collection I Electrolytes I Labs – Blood Loss I Field Chemistry I Colloids – Medication I Crystalloids Administration FluidFluid ResuscitationResuscitation I DehydrationDehydration andand I ShockShock VolumeVolume LossLoss ManagementManagement – Replace Lost Fluid or – Controversial Blood – Definitive therapy = – Often requires 2 -3 Surgery and blood times the amount replacement lost (2:1 rule) – EMS → judicious replacement – Improve end organ perfusion (BP at 90 - 100 mm Hg) EquipmentEquipment andand SuppliesSupplies I FluidsFluids I SuppliesSupplies – Normal Saline – IV Catheters (0.9%
    [Show full text]
  • Intravenous Medicine Administration Self-Directed Learning Package
    Acute Services Division Practice Development Department Intravenous Medicine Administration Self-directed Learning Package Margaret A. Connolly Katherine Hill Lynne Robertson Debbie Thompson Pinky Virhia First published August 2007 Revised July 2014 For review July 2016 Contribution by Christina Ronyane © Practice Development Department, NHS Greater Glasgow and Clyde 2014. All rights reserved. No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying,recording or otherwise without the prior permission of Practice Development Department, NHS GG&C. Acknowledgement of sources of illustrations Figure 1 – page 7 Yellow Card Reproduced with the kind permission of the MHRA. Figure 2 – page 9 Peripheral venous access. Reproduced with the kind permission of Smith and Nephew. Figure 3 – page 10 Midline. Images provided by Vygon (UK) Ltd – © Vygon (UK) Ltd 2012. Figure 4 – page 10 Peripherally inserted central catheter. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 5 – page 10 Non Skin Tunnelled Central Line. Reproduced with the kind permission of Smith and Nephew. Figure 6 – page 11 Skin Tunnelled central venous access. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 7 – page 11 Indwelling Central Venous Access Device. Provided by Vygon (UK) Ltd - © Vygon (UK) Ltd 2012. Figure 10 – page 19 Anaphylaxis algorithm - Reproduced with the kind permission of the Resuscitation Council (UK). Contents Prerequisites for undertaking the IV
    [Show full text]
  • Improvement of Biodistribution with Pegylated Liposomes Containing
    ANTICANCER RESEARCH 31: 153-160 (2011) Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 Liver Tumor-bearing WAG RIJ Rats U. POHLEN, H.J. BUHR and G. BERGER Department of Surgery, Charité Universitaetsmedizin Berlin, Benjamin Franklin Campus, Berlin, Germany Abstract. Aim: To improve the drug concentration in liver metastatic breast cancer develop liver metastases and have a metastases, docetaxel was encapsulated in polyethyleneglycol- poor prognosis, with a median survival of 1-2 years and a 5- liposomes and administered regionally with degradable starch year survival rate of approximately 20% (6, 7). microspheres (DSM). Materials and Methods: A rodent model The most frequently applied chemotherapeutic agent for of solitary metastasis (CC-531 adenocarcinoma) was studied. advanced breast cancer, ovarian cancer and gastric cancer is The animals were randomized into six groups and treated with docetaxel (8-10). 15 ng/kg docetaxel: I: intravenous (i.v.). II: PEG-liposomes Docetaxel inhibits cell proliferation by inducing a i.v.; III: intraartial (i.a.) via the hepatica artery; IV: i.a.) + sustained mitotic block at the metaphase/anaphase anticancer DSM; V: PEG-liposomes i.a.; and VI: PEG-liposomes i.a. + agents in this class promote the polymerization of stable DSM. The docetaxel concentration in the serum, liver and liver microtubules, inhibit their disassembly and profoundly affect tumor at defined times (5, 15, 30, 60,120 240 min and 24 h) a number of key cellular functions that depend on the was measured using HPLC.
    [Show full text]
  • Improving Intravenous Therapy: Opportunities for Designing the Next Generation Infusion System Part 3 – Workflow Efficiency & Cost-Effectiveness
    IMPROVING INTRAVENOUS THERAPY: OPPORTUNITIES FOR DESIGNING THE NEXT GENERATION INFUSION SYSTEM PART 3 – WORKFLOW EFFICIENCY & COST-EFFECTIVENESS AUTHORED BY: Matthew B. Weinger, MD, MS Andrew Kline, BA Department of Anesthesiology, Vanderbilt University School of Medicine INTRODUCTION In this three-part series, we strive to provide an overview of the current status and apparent effectiveness from the user’s point- of-view of infusion pump design. We acknowledge the advances in the field while highlighting opportunities for future improvements. In focusing on some of the usability issues of current pump interfaces and insufficient interoperability, we highlight some of the existing pitfalls and offer human factors-based guidance for next-generation designs. Here, we define infusion pump usability as the relationship We focus on issues related to the between the technology and clinicians’ ability to use that technology general usability, process efficiency and to attain their work goals effectively, safely, efficiently, and with both clinician and patient satisfaction. cost effectiveness of infusion pump use. In this, the third part of the series, we focus on issues related to the general usability, process efficiency and cost effectiveness of infusion pump use. We also address current shortcomings of the integration of infusion pump technology with medication management software. 1 Workflow Efficiency and Cost Effectiveness An important added benefit of optimal pump designs is the prospect of significant cost savings. Each preventable ADE has been reported to cost nearly $9,000,[1] and smart pumps could, through built-in designs to adhere to the “Rights,” decrease the incidence of ADEs (see Part 1 of this series for more information on this topic).
    [Show full text]
  • Intravenous Therapy
    Intravenous therapy What is an intravenous? An intravenous is a thin, plastic tube called a catheter that is put into a vein to give you fluid. The catheter is attached to a solution bag hanging on a pole. This is all called an IV. The type of solution you have depends on your special needs. The IV needs to go into a vein so the blood can carry the fluid around your body. Most often, the IV is put in your hand or forearm. An IV can be put in a foot, upper arm or inner elbow. You may have an IV lock called a saline lock. This means that the catheter is attached to a very short tube with a cap. When it is time for fluid or medication, the cap is taken off and the catheter is attached to a longer tube and solution. This is most often done if you need an IV for medications but do not need extra fluid. Why do I need an IV? There are many reasons for having an IV. Here are some reasons: to give fluids to give medication to give blood or blood products please turn over Intravenous therapy What is an IV pump? Your IV may be connected to an IV pump. The nurses program the pump to deliver the right amount of medications and fluids. It will beep or alarm for different reasons. What activities can I do with an IV? After the IV is put in, there is no needle left in your vein. The tube is held in your vein with tape.
    [Show full text]
  • (Not for IV Bolus Injection) RX ONLY ERAXIS™ (Anidulafungin
    NDA 21-632/S-010 Page 6 [INTRAVENOUS INFUSION, DILUTED WITH STERILE WATER FOR INJECTION] (not for IV Bolus Injection) RX ONLY ERAXIS™ (anidulafungin) FOR INJECTION DESCRIPTION ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4­ yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients: 50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. 100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. The empirical formula of anidulafungin is C58H73N7O17 and the formula weight is 1140.3. The structural formula is: H H OH O HO OC5H11 H O NH HO NH O H C H 3 HN CH N 3 H O H HO O H OH H NH N H3C H H OH HO N O H H H O OH H H OH Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline).
    [Show full text]
  • IV Infusion Therapy Forms
    Intravenous (IV) Infusion Therapy Checklist of what to bring: Your completed Intravenous (IV) Therapy Intake Form A copy of your most recent bloodwork (including G6PD) is helpful Your signed Consent Form Make sure that you are well hydrated prior to your visit; we suggest drinking one to two 16oz. bottles of water. Dehydration can make it difficult to insert an IV. Make sure you eat something prior to you visit; we suggest a high protein snack, such as nuts, seeds, a protein bar, cheese, yogurt, or eggs. Low blood sugar can make you feel weak, light-headed, or dizzy. During your first visit for IV Therapy infusions: During the first visit, the healthcare practitioner will discuss your symptoms and desired outcomes. Based on this assessment, your IV infusion will be customized to address your needs. If you have any complex medical conditions, the healthcare practitioner may request that you obtain blood work and/or your PCP’s approval prior to administering any IV infusions. What to eXpect: The IVs used during your Intravenous (IV) infusion therapy are eXactly the same that you would find in a hospital. Instead of a clinical eXperience though, our IV infusions are given in a peaceful spa setting and leave you feeling calm, relaXed, and refreshed. Depending on your customized IV cocktail, the infusion can be finished in as little as 20- 30 minutes. Our friendly and attentive staff will keep you calm, cared for, and comfortable during your infusion. Patients find the eXperience tranquil and healing. Patients leave feeling vibrant, energized, and refreshed. Flatiron Functional Medicine 400 S.
    [Show full text]
  • Home Health Care (For Nebraska Only) – Community Plan Coverage
    UnitedHealthcare® Community Plan Coverage Determination Guideline Home Health Care (for Nebraska Only) Guideline Number: CS137NE.O Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Community Plan Policies Application ..................................................................................... 1 • Home Hemodialysis (for Nebraska Only) Coverage Rationale ....................................................................... 1 • Private Duty Nursing (PDN) Services (for Nebraska Definitions ...................................................................................... 2 Only) Applicable Codes .......................................................................... 3 • Skilled Care and Custodial Care Services (for References ................................................................................... 11 Nebraska Only) Guideline History/Revision Information ..................................... 11 Instructions for Use ..................................................................... 11 Commercial Policy • Home Health Care Medicare Advantage Coverage Summary • Home Health Services and Home Health Visits Application This Coverage Determination Guideline only applies to the state of Nebraska. Coverage Rationale Indications for Coverage The services being requested must meet all of the following criteria: A written treatment plan must be submitted with the request for specific services and supplies. Periodic review of the written treatment plan may be required for continued Skilled
    [Show full text]